Articles tagged with Vaccination
Researchers found a growing trend of anti-vaccination discourse on Facebook coalescing around the 'civil liberties' argument, which could impact vaccine-related legislation. The study examined over 250,000 posts on 204 Facebook pages and identified three distinct events that contributed to this shift in online discourse.
A University of Sydney-led study found that human-operated Twitter accounts dominate vaccine-related discussions, with most users unlikely to see or engage with bot-generated content. The researchers suggest that resources could be better spent on education interventions and media literacy training.
A 10-week virtual series provides insight into COVID-19 topics for the general public, including vaccine development, mask effectiveness and outbreak tracking. The symposium aims to address community impact and provide solutions.
A large study by Karolinska Institutet found that HPV vaccination significantly reduces the risk of cervical cancer. Women vaccinated at a young age show a 88% reduced risk, while those vaccinated between ages 17 and 30 experience a halved risk.
A Phase 1 trial of an investigational mRNA COVID-19 vaccine has shown that the vaccine is well-tolerated and generates a strong immune response in older adults, with comparable efficacy to younger age groups. The study enrolled 40 healthy volunteers aged 56-71 years, who received two doses of the vaccine.
A survey study explores public preferences for COVID-19 vaccine allocation. The results show that most people prioritize vaccine distribution to high-risk groups, including seniors and individuals with chronic health conditions. This preference is expected to influence healthcare policy decisions.
A cocktail of powerful antibodies from recovered COVID-19 patients locks down the infection machinery, preventing the virus from entering cells. The antibodies protect hamsters from infection when exposed to the coronavirus, also setting off the infection-fighting actions of other immune cells.
Researchers at DZNE identified effective antibodies against SARS-CoV-2, which could trigger undesired side effects when binding to various organs. These neutralizing antibodies can prevent the virus from entering cells and reproducing, helping immune cells eliminate the pathogen.
A new CRISPR vaccine has been successfully tested in animal studies, providing protection against the parasitic skin disease leishmaniasis. The vaccine uses a modified version of the parasite that causes the disease, which induces immunity without causing clinical disease.
A recent survey found that more people are wearing masks in public places, while vaccine uncertainty is also increasing. The study suggests that addressing efficacy concerns through messaging may be key to reaching those not wearing masks. Respondents perceived a higher risk of getting seriously ill and dying from COVID-19 than is likely.
A new review article reveals that COVID-19 mortality rates are significantly higher among men than women, with sex-based physiological differences potentially contributing to the increased risk. The study highlights the importance of considering sex as a key variable in research related to immunity and infectious disease.
Researchers investigating BCG vaccination's potential COVID-19 protection find no correlation between infancy vaccination and reduced pandemic cases. Instead, they suggest other factors like public health agency strength or risk aversion may play a role.
Colorado State University has received a $3.1 million grant from the National Institutes of Health to continue developing the SolaVAX coronavirus vaccine candidate. The funding will support pre-clinical research and human clinical trials to test the safety and immune response of the vaccine.
A new study reveals that believing in COVID-19 conspiracy theories predicts increased resistance to vaccination and preventive behaviors, including mask-wearing. The researchers found a widening gap between those who strongly believed in conspiracies and those who did not, with believers being less likely to wear masks and get vaccinated.
A study by Princeton researchers projects that a vaccine capable of eliciting strong immune responses can substantially reduce future COVID-19 cases. The study found that the nature of immune responses affects clinical outcomes and the burden of severe cases, with stronger immunity reducing future burdens.
A team of researchers adapted standard epidemiological models to explore how COVID-19 pandemic trajectories might unfold in the next five years. Their work emphasizes the importance of understanding adaptive immune responses and vaccine efficacy in determining future case severity and duration.
Researchers develop a novel approach to detect and defend against hardware Trojans by adapting human immune system principles. The proposed mechanism uses an irregular network topology and machine learning-based anomaly detection to identify malicious attacks.
The Society for Healthcare Epidemiology of America recommends immunizations against vaccine-preventable diseases for healthcare personnel, educators, and students. Medical contraindications are the only exception to receiving recommended immunizations.
A University of Illinois expert warns that DIY COVID-19 vaccines can be dangerous and undermine public trust in vaccines. The development of homemade medical interventions lacks the rigorous testing and safety protocols required by law, posing significant risks to public health.
The article examines the evidence for vaccinating children against COVID-19, highlighting both benefits and drawbacks. Experts consider factors such as vaccine efficacy, side effects, and long-term health implications in making their case for or against mandates.
Researchers analyzed COVID-19 patients' antibody responses to guide vaccine development, finding that neutralizing activity typically drops within one month post-hospital discharge and severe cases have non-neutralizing antibodies contributing to reinfection risk.
Public confidence in vaccines varies widely between countries, with signs of improvement in parts of Europe but growing scepticism in others. The study found that six countries experienced substantial increases in people strongly disagreeing vaccines are safe, mirroring trends in political instability and religious extremism.
A new model prioritizes countries based on premature deaths caused by COVID-19, focusing on mitigating three types of harms: death and permanent organ damage, indirect health consequences, and economic destruction. The Fair Priority Model aims to reduce premature deaths and other irreversible health consequences from COVID-19.
A new Fair Priority Model proposes mitigating three types of COVID-19 harms: death, organ damage, healthcare strain, and economic destruction. The model aims to benefit people and limit harm while prioritizing the disadvantaged and giving equal moral concern to all individuals.
Researchers at Ohio State University developed a novel vaccine technique that induces antibodies against SARS-CoV-2 by boosting antigen production. In animal studies, the treatment successfully produced antibodies against the virus within a month.
Scientists have developed a controlled human hookworm infection model to accelerate vaccine development, with the goal of preventing infections that affect 576-740 million people worldwide. The study will evaluate two lead vaccine antigens and assess their efficacy in a phase II trial.
The new guidelines update recommendations for feline vaccinations, encouraging veterinarians to consider individualized risk factors and lifestyle-based vaccine calculators. The guidelines aim to improve feline wellbeing by providing tailored vaccination protocols and educating pet owners about the importance of vaccination.
The BCG vaccine has been shown to protect elderly people against various respiratory infections, including those of viral origin. This protective effect was observed in a double-blind randomized clinical study, which found that BCG-vaccinated participants had 75% fewer respiratory infections than placebo recipients.
The FDA's emergency use authorization process for COVID-19 vaccines was criticized for its speed and lack of rigor. The researchers propose four reforms to enhance accountability and transparency in drug authorizations and approvals, including improved risk assessment and post-marketing surveillance.
The introduction of pneumococcal conjugate vaccine PCV13 has significantly reduced socioeconomic disparities and Black-white-based racial disparities for invasive pneumococcal disease. The study found a large decrease in the overall incidence of pneumococcal disease and markedly reduced race-based disparities.
A recent study found that prior Zika virus infection can enhance the risk of severe dengue disease. The research used a cohort from Nicaragua to confirm previous reports on cross-reactive antibodies between Zika and dengue viruses. The findings have important implications for developing effective vaccines against both diseases.
A new mouse model developed at UNC-Chapel Hill has captured many features of human COVID-19 disease, advancing the development of vaccines and therapeutics. The model has shown promise in protecting mice from infection with various treatments, including mRNA-1273 vaccine candidate.
The Cambridge-developed DNA vaccine candidate, DIOS-CoVax2, targets key regions of the virus to produce beneficial anti-viral responses. The vaccine aims to protect against SARS-CoV-2 and other related coronaviruses, with a potential for widespread use and low-cost manufacturing.
A study found that belief in negative vaccination misperceptions has a strong impact on policy views, with 20% of Americans holding negative views about vaccination. Strong support for mandatory childhood vaccinations was observed, but opposition to religious and personal belief exemptions remained significant.
A new vaccine candidate has been developed for HHV-6B, a virus that causes exanthem subitum in infants. The vaccine targets the gH/gL/gQ1/gQ2 complex and induces strong immunity against the virus. Animal experiments have shown that the vaccine prevents HHV-6B infection and activates dendritic cells to induce innate immunity.
Researchers have developed a promising COVID-19 vaccine candidate using virus-like particles (VLPs) that mimic the native SARS-CoV-2 virus. The VLP platform has shown success in stimulating immune responses against other viruses like HPV and HepB.
Researchers at the University of Wisconsin-Madison discovered that patients taking opioid painkillers produce anti-opioid antibodies, which may limit the benefit of an anti-opioid vaccine. The study found a correlation between recent opioid dose exposure and antibody production.
A University of Washington team is developing a model to simulate the impact of various interventions on population health outcomes during the COVID-19 pandemic. The model will generate policy recommendations that could help lower infections in King County.
The large-scale production of COVID-19 vaccines will necessitate the sharing of manufacturing knowledge to ensure rapid and effective scale-up. This includes disclosure of necessary information from patents, which can facilitate international collaboration and standardization.
A study found that independent search engines often return anti-vaccine websites, while internet giants like Google.com typically do not. This raises concerns about the spread of misinformation and its impact on vaccine hesitancy.
A new study found that countries with higher TB vaccination coverage have significantly improved COVID-19 outcomes, particularly in younger populations. The researchers analyzed data from 55 countries and found a constant association between BCG vaccine administration and COVID-19 outcomes.
A new oral anthrax vaccine is being developed by Texas A&M researchers to protect livestock and wildlife from the deadly disease. The vaccine, which uses a gel-like suspension of live bacteria, could potentially be distributed through bait to reach animals more easily.
A new experimental COVID-19 vaccine has been shown to prevent pneumonia and elicit high levels of protective antibodies in mice infected with the virus. The vaccine uses a mild virus genetically modified to carry a key gene from the COVID-19 virus, generating a strong immune response.
A new vaccine candidate BCG::RD1 has shown highly protective effects against tuberculosis in older mice with type 2 diabetes. The vaccine acts on multiple immune cell subsets to mount a robust response against TB-causing bacteria.
A new study demonstrates the potential of an intranasal vaccine platform using self-assembling peptide nanofibers tagged with antigens, inducing an immune response and activating T cells without adjuvants. This technology offers a safer and more effective alternative for generating long-lasting immunity against diseases.
Researchers are developing and testing technology for delivering vaccine doses via the skin using microneedles. This innovative approach aims to improve patient compliance and yield better health outcomes, with potential benefits including reduced burden on healthcare systems and increased accessibility for self-administration at home.
A recent study published in Cell Reports Medicine found that the BCG vaccine is safe and does not increase the risk of COVID-19 symptoms. The research also suggests a cautiously positive picture, with lower numbers of sick people and extreme fatigue among vaccinated individuals during the pandemic.
The investigational vaccine induced neutralizing antibodies in mice, providing protection against SARS-CoV-2 infection. Additionally, mice challenged with the virus after a single dose showed protection against viral replication in the lung, indicating potential efficacy in humans.
A study published in Acta Obstetricia et Gynecologica Scandinavica found that HPV vaccination significantly reduces the risk of high-grade cervical intraepithelial neoplasia, a precancerous condition leading to cervical cancer. Vaccination coverage was high among young women born in 1993, resulting in a 30% lower risk compared to those...
A carefully engineered spike protein stabilizer has aided in the development of a new COVID-19 vaccine. The stabilizer, known as S-2P protein, keeps infection from spreading and prompts a helpful immune response.
A study found that countries with mandatory BCG vaccination until 2000 exhibited slower infection and death rates during the initial COVID-19 outbreak. Researchers estimated that only 468 people would have died in the US if mandatory BCG vaccination had been implemented decades earlier.
Researchers created a new mouse model to study viral responses and test COVID-19 vaccines. The model, based on an adapted SARS-CoV-2 strain, showed promise in protecting vaccinated mice from disease.
An experimental COVID-19 vaccine demonstrated robust immune responses and rapid viral control in the upper and lower airways of rhesus macaques. The vaccine reduced replicating virus in the lungs and upper airway, which could limit disease progression and transmission.
Clinical studies in Kenya suggest that iron deficiency during infancy may reduce the protection provided by vaccinations. In one study, researchers found that anaemic infants had more than twice the risk of lacking protective antibodies against diphtheria and other pathogens.
A team of researchers from SMART has developed a novel approach to induce strong and broad immunity against the dengue virus. Sequential immunization was found to be more effective in inducing higher levels of neutralizing antibodies to all four DENV serotypes than traditional tetravalent-formulated immunization.
A comprehensive review of vaccine data over 20 years found vaccines to be remarkably safe, with most safety issues identified through existing postmarketing surveillance programs. The study confirms the effectiveness of the vaccine approval system and postmarketing surveillance in ensuring public health benefits while minimizing risks.
A Phase III vaccine trial will be conducted at UC San Diego, recruiting up to 500 participants to assess the efficacy and immunogenicity of a Moderna-developed vaccine. The trial aims to demonstrate the vaccine's ability to prevent COVID-19 and severe symptoms, with results expected by end of year.
A new mRNA-based vaccine candidate, ARCoV, elicits protective immunity in mice and non-human primates, preventing SARS-CoV-2 infection. The vaccine induces high levels of neutralizing antibodies and T cell responses, offering broad protection against different strains.
Researchers at the University of Texas at Austin have successfully redesigned a key protein from the coronavirus, enabling faster and more stable vaccine production. The new design, called HexaPro, produces up to 10 times more protein than an earlier version, potentially reducing vaccine doses or speeding up production.
Researchers are working on experimental gene-based vaccines using harmless viruses or DNA/RNA to deliver genetic information to human cells. The technology is fast but largely unproven, and concerns remain about neutralization levels and safety. Multiple types of vaccines will likely be needed to ensure effective immunity.